7 trends in life sciences investment this week
From 12 November 2026 to 18 November 2026, 28 biotech and health care companies reported $141.9 million of new private money in SEC Form D filings (company count up 44% on the 4-week average of 19.5), and companies registered 71 new trials, 22 of them at Phase 3.
As of . Research from public records, not investment advice.
- Venture money into biotech and health care: 28 operating companies reported Form D sales, $141.9 million in total. Companies up 44% on the 4-week average of 19.5; money down 24% on the 4-week average of $186.4 million.Source: SEC Form D
- Largest biotech or health care raise: Pelthos Therapeutics Inc. sold $57.5 million. Pharmaceuticals, Form D filed 16 November 2026.Source: SEC Form D
- New company-sponsored trials: 71 registered. Up 23% on the 4-week average of 57.8.Source: ClinicalTrials.gov
- New company-sponsored Phase 3 trials: 22 registered. Level with the 4-week average of 21.3.Source: ClinicalTrials.gov
- Medicines stepping up a phase: 6 medicines entered a higher trial phase. Tuesday's list has the 12 largest.Source: ClinicalTrials.gov
- Disease with the most new company trials: Diabetes Mellitus, Type 2, 2 new trials.Source: ClinicalTrials.gov
- Medicine approvals: 3 approvals recorded. Down 29% on the 4-week average of 4.3.Source: FDA
How this list is made
Each line compares the 7 days to yesterday with the average of the 4 weeks before; a line is left out while its source has no record for the week yet. Raises are SEC Form D sales by operating biotech, pharmaceutical and health care companies (funds and vehicles left out). Trials are registrations on ClinicalTrials.gov; approvals, clearances and warning letters come from FDA records.
Sources: SEC EDGAR, Form D, ClinicalTrials.gov, FDA.